We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical needs. The company's product candidate consists of KarXT, for the treatment of acute psychosis in patients with schizophrenia, which are in clinical stage. Karuna Therapeutics Inc. is based in Boston, Massachusetts.
- Recent KRTX Stock Price: $258.89
- Yearly Gain for KRTX stock: 103.77%
- Market Cap for KRTX stock: $6.84B
- P/E Ratio for KRTX stock: -33.647
Will KRTX's stock price go up? Is there an accurate KRTX stock forecast available?
TipRanks.com reports that Karuna Therapeutics currently has 14 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $241.07. The target pricing ranges from a high KRTX forecast of $315.00 down to a low forecast of $160.00. Karuna Therapeutics (KRTX)’s last closing stock price was $258.89 which would put the average price target at -6.88% upside.
In addition, TradingView issued a Strong Buy rating for KRTX stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on KRTX stock.
Other analysts covering KRTX include:
- Marc Goodman of SVB Securities issued a Buy rating with the price target of $ 270 on 1 day ago
- Jason Gerberry of Bank of America Securities issued a Buy rating with the price target of $ 261 on 1 day ago
- Corinne Jenkins of Goldman Sachs issued a Buy rating with the price target of $ 278 on 1 day ago
- Jason McCarthy of Maxim Group issued a Buy rating with the price target of $ 300 on 1 day ago
If you are wondering if KRTX is a good stock to buy, here are 3rd party ratings for KRTX stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 31% (78 out of 252)
What is the sentiment on the street regarding Karuna Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for KRTX stock: Very Bullish
- Blogger Consensus for KRTX stock: Bullish
- Media Buzz for KRTX stock: Very High
- Insider Signal for KRTX stock: Positive
- Investor Sentiment for KRTX stock: Very Positive
- Hedge Fund signal for KRTX stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on KRTX stock including scouring the social networks like KRTX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for KRTX stock chart >>
Summary: Apellis Pharmaceuticals, Inc. is a clinical-stage biotech focused on the development of novel therapeutics, which work through the inhibition of the complement system, specially targeting the C3 protein of the complement system to treat autoimmune and inflammatory diseases.
- Recent APLS Stock Price: $66.44
- Yearly Gain for APLS stock: 10.84%
- Market Cap for APLS stock: $6.85B
- P/E Ratio for APLS stock: -9.499
Will APLS's stock price go up? Is there an accurate APLS stock forecast available?
TipRanks.com reports that Apellis Pharmaceuticals currently has n/a analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is n/a. The target pricing ranges from a high APLS forecast of n/a down to a low forecast of n/a. Apellis Pharmaceuticals (APLS)’s last closing stock price was $66.44 which would put the average price target at 14.64% upside.
In addition, TradingView issued a Strong Buy rating for APLS stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on APLS stock.
Other analysts covering APLS include:
- Madhu Kumar of Goldman Sachs issued a Buy rating with the price target of $ 102 on 1 day ago
- Phil Nadeau of Cowen & Co. issued a Buy rating with the price target of $ 70 on 1 day ago
- Steven Seedhouse of Raymond James issued a Buy rating with the price target of $ 113 on 1 day ago
- Annabel Samimy of Stifel Nicolaus issued a Buy rating with the price target of $ 60 on 1 day ago
If you are wondering if APLS is a good stock to buy, here are 3rd party ratings for APLS stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 31% (78 out of 252)
What is the sentiment on the street regarding Apellis Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for APLS stock: Neutral
- Blogger Consensus for APLS stock: ―
- Media Buzz for APLS stock: Medium
- Insider Signal for APLS stock: Negative
- Investor Sentiment for APLS stock: Neutral
- Hedge Fund signal for APLS stock: Positive
The stock market is extremely volatile, and you need to do your own research on APLS stock including scouring the social networks like APLS StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for APLS stock chart >>
Summary: MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland.
- Recent MGNX Stock Price: $4.98
- Yearly Gain for MGNX stock: -79.24%
- Market Cap for MGNX stock: $312.80M
- P/E Ratio for MGNX stock: -1.429
Will MGNX's stock price go up? Is there an accurate MGNX stock forecast available?
TipRanks.com reports that MacroGenics currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $12.86. The target pricing ranges from a high MGNX forecast of $35.00 down to a low forecast of $4.00. MacroGenics (MGNX)’s last closing stock price was $4.98 which would put the average price target at 158.23% upside.
In addition, TradingView issued a Neutral rating for MGNX stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MGNX stock.
Other analysts covering MGNX include:
- Etzer Darout of BMO Capital issued a Hold rating with the price target of $ 4 on 1 day ago
- Peter Lawson of Barclays issued a Buy rating with the price target of $ 8 on 1 day ago
- Silvan Tuerkcan of JMP Securities issued a Buy rating with the price target of $ 20 on 1 day ago
- Jonathan Chang of SVB Securities issued a Buy rating with the price target of $ 12 on 1 day ago
If you are wondering if MGNX is a good stock to buy, here are 3rd party ratings for MGNX stock:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Bottom 41% (149 out of 252)
What is the sentiment on the street regarding MacroGenics? (Current ratings compiled by TipRanks.com)
- News Sentiment for MGNX stock: Bullish
- Blogger Consensus for MGNX stock: Bullish
- Media Buzz for MGNX stock: Very High
- Insider Signal for MGNX stock: Positive
- Investor Sentiment for MGNX stock: Very Negative
- Hedge Fund signal for MGNX stock: Neutral
The stock market is extremely volatile, and you need to do your own research on MGNX stock including scouring the social networks like MGNX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MGNX stock chart >>
Summary: Alignment Healthcare Inc. is a consumer-centric platform delivering customized health care in the United States to seniors and those who need it most, the chronically ill and frail, through its Medicare Advantage plans. Alignment Healthcare Inc. is based in ORANGE, Calif.
- Recent ALHC Stock Price: $16.5
- Yearly Gain for ALHC stock: -8.54%
- Market Cap for ALHC stock: $3.17B
- P/E Ratio for ALHC stock: -20.701
Will ALHC's stock price go up? Is there an accurate ALHC stock forecast available?
TipRanks.com reports that Alignment Healthcare currently has n/a analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is n/a. The target pricing ranges from a high ALHC forecast of n/a down to a low forecast of n/a. Alignment Healthcare (ALHC)’s last closing stock price was $16.5 which would put the average price target at 23.82% upside.
In addition, TradingView issued a Buy rating for ALHC stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ALHC stock.
Other analysts covering ALHC include:
- John Ransom of Raymond James issued a Buy rating with the price target of $ 22 on 2 days ago
- Kevin Caliendo of UBS issued a Hold rating with the price target of $ 17 on 2 days ago
- Kevin Fischbeck of Bank of America Securities issued a Buy rating with the price target of $ 23 on 2 days ago
- Nathan Rich of Goldman Sachs issued a Buy rating with the price target of $ 21 on 2 days ago
If you are wondering if ALHC is a good stock to buy, here are 3rd party ratings for ALHC stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 38% (96 out of 252)
What is the sentiment on the street regarding Alignment Healthcare? (Current ratings compiled by TipRanks.com)
- News Sentiment for ALHC stock: Very Bullish
- Blogger Consensus for ALHC stock: Bullish
- Media Buzz for ALHC stock: Medium
- Insider Signal for ALHC stock: Negative
- Investor Sentiment for ALHC stock: ―
- Hedge Fund signal for ALHC stock: Neutral
The stock market is extremely volatile, and you need to do your own research on ALHC stock including scouring the social networks like ALHC StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ALHC stock chart >>
Summary: Kymera Therapeutics Inc. is a biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics for degrade dysregulated, disease-causing proteins to address previously intractable disease targets. Kymera Therapeutics Inc. is based in Watertown, United States.
- Recent KYMR Stock Price: $34.05
- Yearly Gain for KYMR stock: -51.81%
- Market Cap for KYMR stock: $1.57B
- P/E Ratio for KYMR stock: -11.195
Will KYMR's stock price go up? Is there an accurate KYMR stock forecast available?
TipRanks.com reports that Kymera Therapeutics currently has 8 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $56.38. The target pricing ranges from a high KYMR forecast of $93.00 down to a low forecast of $26.00. Kymera Therapeutics (KYMR)’s last closing stock price was $34.05 which would put the average price target at 65.58% upside.
In addition, TradingView issued a Strong Buy rating for KYMR stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on KYMR stock.
Other analysts covering KYMR include:
- Andrew Fein of H.C. Wainwright issued a Buy rating with the price target of $ 85 on 23 hours ago
- Zhiqiang Shu of Berenberg Bank issued a Buy rating with the price target of $ 68 on 23 hours ago
- Leah R. Cann of Brookline Capital Markets issued a Buy rating with the price target of $ 93 on 1 day ago
- Chris Shibutani of Goldman Sachs issued a Buy rating with the price target of $ 40 on 1 week ago
If you are wondering if KYMR is a good stock to buy, here are 3rd party ratings for KYMR stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 31% (78 out of 252)
What is the sentiment on the street regarding Kymera Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for KYMR stock: Neutral
- Blogger Consensus for KYMR stock: ―
- Media Buzz for KYMR stock: Very High
- Insider Signal for KYMR stock: Positive
- Investor Sentiment for KYMR stock: Very Positive
- Hedge Fund signal for KYMR stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on KYMR stock including scouring the social networks like KYMR StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for KYMR stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================